Hoegaarden, Belgium

Pall Life Sciences Belgium Bvba

USPTO Granted Patents = 7

% Expired Patents = 28.6


Forward Citations = 8

Loading Chart...
Loading Chart...

13 inventors (with patents filed for the assignee):

goldMedal Jean-Pascal Zambaux (5 out of 16 patents)

silverMedal Steven Vanhamel (2 out of 5 patents)

bronzeMedal Tom Claes (2 out of 4 patents)

4.  Vishwas Pethe (1 out of 4 patents)

5.  José Castillo (1 out of 21 patents)

6.  Suresh Purushothaman (1 out of 1 patent)

7.  Jose Antonio Castillo Gonzalez (1 out of 3 patents)

8.  Jean-Christophe Drugmand (1 out of 3 patents)

9.  Derek Pendlebury (1 out of 1 patent)

10.  Fabien Moncaubeig (1 out of 1 patent)

11.  Christophe Braet (1 out of 2 patents)

12.  Florence Bosco (1 out of 5 patents)

13.  Yvan Corten (1 out of 1 patent)


7 patents:

Company Overview
Pall Life Sciences Belgium Bvba is a global leader in filtration, separation, and purification solutions for a wide range of industries and applications. With a strong commitment to innovation and customer satisfaction, Pall Life Sciences Belgium Bvba offers cutting-edge technologies and products that help customers improve efficiency, reduce costs, and ensure product quality. Their solutions are used in biopharmaceutical, food and beverage, laboratory, and industrial processes around the world.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

7 Patents

#1 in Hoegaarden

#338 in Belgium

Hoegaarden, BE
Hoegaarden, Belgium
Forward Citations = 8

13 inventors:

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Pall Life Sciences Belgium Bvba. Retrieved from https://idiyas.com/company/pall-life-sciences-belgium-bvba

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…